Form 4: aTyr Pharma Director Svetlana Lucas Acquires Stock Options

Director Svetlana Lucas acquired 24,000 stock options in aTyr Pharma on May 22, 2024, according to a Form 4 filing.

Summary

• Svetlana Lucas, a director of aTyr Pharma, acquired 24,000 stock options on May 22, 2024.
• The options have an exercise price of $1.86.
• These options were granted pursuant to the Issuer's non-employee director compensation policy.
• The options vest in full on the earlier of May 22, 2025, or the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• Following the transaction, Lucas directly owns 24,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard director compensation practice. It's neither overwhelmingly positive nor negative.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the Board of Directors.

Industry Context

This is a standard practice for compensating board members in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders.
• The vesting schedule and exercise price are typical for director compensation packages.
• Comparable companies often use similar equity-based compensation plans to attract and retain qualified board members.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates